Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: Clinical correlation

Leukemia

Volumn 21, Issue 9, 2007, Pages 1984-1991

  Rodriguez A ^a   Villuendas, R ^a   Yanez L ^b   Gomez M E ^c   Diaz R ^a   Pollan M ^d   Hernandez N ^c   de la Cueva, P ^a   Marin M C ^a   Swat, A ^a   Ruiz, E ^e   Cuadrado, M A ^b   Conde, E ^b   Lombardia L ^a   Cifuentes, F ^f   Gonzalez, M ^g   Garcia Marco J A ^h   Piris, M A ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d CARLOS III INSTITUTE OF HEALTH   (Spain)

^e HOSPITAL VIRGEN DE LA SALUD   (Spain)

^f AGILENT TECHNOLOGIES   (United States)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; VALIDATION STUDY;

EID: 34548128321     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404831     Document Type: Article

References (34)

1. Dighiero G. CLL biology and prognosis. Hematology (Am Soc Hematol Educ Program) 2005; 1: 278-284.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
3. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-864.
4. Rai KR, Montserrat E. Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 1987; 24: 252-256.
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
6. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
8. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
9. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
10. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16: 30-35.
11. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-2434.
12. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
13. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
14. Van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006; 91: 56-63.
15. Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106: 650-657.
16. Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216-1223.
17. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625-1638.
18. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
19. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
20. Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L et al. Identification of genes involved in resistance to interferon-alpha In cutaneous T-cell lymphoma. Am J Pathol 2002; 161: 1825-1837.
21. Rodriguez A, Martinez N, Camacho Fl, Ruiz-Ballesteros E, Algara P, Garcia JF et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 2004; 10: 6796-6806.
22. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
23. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389-4395.
24. Ingham RJ, Santos L, Dang-Lawson M, Holgado-Madruga M, Dudek P, Maroun CR et al. The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem 2001; 276: 12257-12265.
25. Raman C, Kuo A, Deshane J, Litchfield DW, Kimberly RP. Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. J Biol Chem 1998; 273: 19183-19189.
26. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780-786.
27. Leitges M, Sanz L, Martin P, Duran A, Braun U, Garcia JF et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 2001; 8: 771-780.
28. Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware CF, Yagita H et al. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem 1996; 271: 14661-14664.
29. Nishiu M, Yanagawa R, Nakatsuka S, Yao M, Tsunoda T, Nakamura Y et al. Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: Identification of genes related to disease progression. Jpn J Cancer Res 2002; 93: 894-901.
30. Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep 2003; 4: 307-312.
31. Park MY, Jang HD, Lee SY, Lee KJ, Kim E. Fas-associated factor-1 inhibits nuclear factor-kappaB (NF-kappaB) activity by interfering with nuclear translocation of the ReIA (p65) subunit of NF-kappaB. J Biol Chem 2004; 279: 2544-2549.
32. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
33. Huttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nuckel H et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006; 20: 1774-1782.
34. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-4614.